Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Yen, Chia-Jui"'
Autor:
Dufour, Jean-François, Schwartz, Jonathan D, Zhu, Andrew X, Pastorelli, Davide, Chau, Ian, REACH Trial, Investigators., Chang, Shao-Chun, Okusaka, Takuji, Ryoo, Baek-Yeol, Chung, Hyun Cheol, Blanc, Jean-Frederic, Trojan, Jorg, Sastre, Javier, Kubackova, Katerina, Abada, Paolo B, Yen, Chia-Jui, Yang, Ling, Pfiffer, Tulio Eduardo Flesch, Kudo, Masatoshi, Baron, Ari D, Poon, Ronnie, Park, Joon Oh
Publikováno v:
The Lancet Oncology. 16:859-870
Background: VEGF and VEGF receptor-2-mediated angiogenesis contribute to hepatocellular carcinoma pathogenesis. Ramucirumab is a recombinant IgG1 monoclonal antibody and VEGF receptor-2 antagonist. We aimed to assess the safety and efficacy of ramuci
Autor:
Marc Pracht, Kenta Motomura, Philippe Merle, Richard S. Finn, Jean-Baptiste Hiriart, Takuji Okusaka, Christophe Borg, Paolo Abada, Masatoshi Kudo, Dong Bok Shin, Guido Gerken, Eric Assenat, Chia Jui Yen, Izumi Ohno, Yoon-Koo Kang, Kun-Ming Rau, Bruno Daniele, Yanzhi Hsu, Andrew X. Zhu, Josep M. Llovet, Peter R. Galle, Manabu Morimoto, Giovanni Brandi, Ho Yeong Lim
Publikováno v:
The Lancet Oncology
The Lancet Oncology, 2019, 20 (2), pp.282-296. ⟨10.1016/S1470-2045(18)30937-9⟩
The Lancet Oncology, 2019, 20 (2), pp.282-296. ⟨10.1016/S1470-2045(18)30937-9⟩
Background: Patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations have poor prognosis. We aimed to establish the efficacy of ramucirumab in patients with advanced hepatocellular carcinoma and α-fetoprotein conce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c659e7762c4ea8ec28743092b9b3bf4c
https://www.ncbi.nlm.nih.gov/pubmed/30665869
https://www.ncbi.nlm.nih.gov/pubmed/30665869